Fundraising FoxKhloris Biosciences
South San Francisco, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Khloris Biosciences
Sign up to see every warm intro you have to Khloris Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Khloris Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.
Founders & leadership
JC
Joseph C. WuNamed on SEC filing
LA
Lynne A. BuiCo-Founder, President, CEO, and Chairman of the Board
Investors · 1
Leaps by BayerreportedLeverkusen
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2018
▶$5MraisedDec 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedDec 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph C. WuDirector
- Lynne A. BuiExecutive Officer, Director
- Amount sold
- $5M
- Minimum investment
- $100K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Claris BioClaris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Chrysalis BiotherapeuticsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
AmbrosiabiosciencesAmbrosia Biosciences is a drug discovery company developing orally delivered, small molecule therapies for obesity and other metabolic disorders. It operates U.S.-based biology and chemistry laboratories along with an NMR facility and structural biology and computational chemistry capabilities to advance programs from hit to IND.
Companies working in the same space as Khloris Biosciences.
In the news
Frequently asked questions
- What does Khloris Biosciences do?
- Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.
- Who are Khloris Biosciences's investors?
- Khloris Biosciences's investors include Leaps by Bayer.
- How much funding has Khloris Biosciences raised?
- Khloris Biosciences has disclosed $5M raised across 1 round.
- Where is Khloris Biosciences headquartered?
- Khloris Biosciences is headquartered in South San Francisco, US.